Key Takeaways
- • Prenetics' IM8 health supplement brand secured US$1 billion in non-dilutive growth financing from General Catalyst's Customer Value Fund (CVF), enabling aggressive expansion of global marketing and brand-building initiatives.
- • The financing structure is innovative: CVF will fund up to 70% of IM8's monthly marketing spend in exchange for a capped return based on customer acquisition cohorts, aligning investor returns with unit economics rather than equity dilution.
- • IM8 demonstrates strong customer unit economics, with every dollar spent on customer acquisition generating US$1.44 in gross profit—a metric that CEO Danny Yeung indicates is improving monthly due to the subscription model's recurring revenue nature.
- • The brand, co-founded in December 2024 by Prenetics CEO Danny Yeung and English football legend David Beckham, generated approximately US$33 million in revenue and has achieved rapid market traction in the direct-to-consumer health and wellness sector.
- • Prenetics, a Nasdaq-listed consumer health company founded in 2014, is leveraging this capital to accelerate its ambition to build a multi-billion-dollar global consumer health brand.
Summary
Prenetics' IM8 health supplement brand has secured up to US$1 billion in growth financing from General Catalyst's Customer Value Fund, marking a significant capital injection for the rapidly scaling direct-to-consumer wellness company. The non-dilutive financing structure differs from traditional equity investment: CVF will fund up to 70% of IM8's monthly marketing spend in exchange for a capped return calculated based on customer acquisition cohorts. This model allows IM8 to accelerate customer acquisition without surrendering equity ownership, addressing investor concerns regarding the company's customer acquisition spending.
IM8's unit economics demonstrate the strength of its business model. CEO Danny Yeung disclosed that every dollar spent acquiring customers has generated US$1.44 in gross profit to date, with this metric improving monthly. For a company with a subscription-based model, this positive customer lifetime value relative to acquisition cost validates the aggressive marketing spend strategy and supports the rationale for scaling capital deployment. Yeung, who founded Prenetics in 2014 and took it public in 2022, emphasized that General Catalyst's due diligence process was "the deepest" he has experienced as a founder, underscoring the rigor applied to evaluate the business model's sustainability.
IM8, co-founded in December 2024 by Yeung alongside English football legend David Beckham, has already achieved material traction. The brand generated approximately US$33 million in revenue and specializes in all-in-one nutritional supplement powders targeting health, wellness, and longevity consumers. The involvement of a high-profile celebrity co-founder and the brand's positioning in the premium direct-to-consumer segment have contributed to rapid early growth. Yeung stated the company's ambition is to build a multi-billion-dollar global consumer health brand, with the General Catalyst partnership materially accelerating that path through expanded marketing capacity and geographic reach.
This financing reflects continued investor appetite for direct-to-consumer health and wellness companies demonstrating strong unit economics and recurring revenue models. General Catalyst's Customer Value Fund focus on performance-based capital structures aligns with the institutional shift toward outcome-oriented investment vehicles in the consumer sector.
IM8's unit economics demonstrate the strength of its business model. CEO Danny Yeung disclosed that every dollar spent acquiring customers has generated US$1.44 in gross profit to date, with this metric improving monthly. For a company with a subscription-based model, this positive customer lifetime value relative to acquisition cost validates the aggressive marketing spend strategy and supports the rationale for scaling capital deployment. Yeung, who founded Prenetics in 2014 and took it public in 2022, emphasized that General Catalyst's due diligence process was "the deepest" he has experienced as a founder, underscoring the rigor applied to evaluate the business model's sustainability.
IM8, co-founded in December 2024 by Yeung alongside English football legend David Beckham, has already achieved material traction. The brand generated approximately US$33 million in revenue and specializes in all-in-one nutritional supplement powders targeting health, wellness, and longevity consumers. The involvement of a high-profile celebrity co-founder and the brand's positioning in the premium direct-to-consumer segment have contributed to rapid early growth. Yeung stated the company's ambition is to build a multi-billion-dollar global consumer health brand, with the General Catalyst partnership materially accelerating that path through expanded marketing capacity and geographic reach.
This financing reflects continued investor appetite for direct-to-consumer health and wellness companies demonstrating strong unit economics and recurring revenue models. General Catalyst's Customer Value Fund focus on performance-based capital structures aligns with the institutional shift toward outcome-oriented investment vehicles in the consumer sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.